Nuvation Bio Reports Preliminary Q4 Revenue and Analyst Price Target Adjustment
Nuvation Bio announced preliminary Q4 2025 revenue of $15.7M for IBTROZI and a $25M milestone payment. H.C. Wainwright adjusted its price target while maintaining a Buy rating.